Biopharmaceutical Product Attributes and Biological Consequences Community

 View Only

Opportunity to Influence AAPS / BPABC Community 2025 OSDs and PharmSci 360 Programming

  • 1.  Opportunity to Influence AAPS / BPABC Community 2025 OSDs and PharmSci 360 Programming

    Community Leadership
    Posted 03-11-2025 23:07

    Hello BPABC Community,

    We are busy planning programming for 2025. Currently, we are focused on the AAPS annual conference (PharmSci 360), and we intend to submit proposals focused on biologic consequences of biotherapeutics (e.g., setting clinically relevant specifications, predictive in vitro assays). 

    But we would love input on areas of interest to YOU (our members):

    1. If you have any scientific topics you would like to see at PharmSci 360, please respond to the following poll by Friday March 14th.    https://forms.gle/BboYoVpJm4EEpaxZ9
    2. Additionally, your submitted topics can be incorporated into Open Scientific Discussions (OSDs) throughout 2025. So please do not be shy with submitting any ideas.

    You are also welcome to directly submit proposals for PharmSci 360directly to AAPS through their website: Submit Programming - American Association of Pharmaceutical Scientists

    As a reminder, we had a great line-up of OSDs in 2024:

    ·         "How to analyze 'unwanted particles' in the presence of 'wanted particles'",  Tim Menzen, PhD (Coriolos Pharma)

    ·         "Issues and Challenges for Particle Characterization in Biotherapeutics", Linda Narhi, PhD (BioPhia Consulting and UCSB)

    ·         "Recent Advances in Combining AI & Microscopy to Analyze and Monitor Biologics: Applications to Protein and Cell-Based Therapeutics", Chris Calderon, PhD (Ursa Analytics and Univ. of Colorado, Boulder)

    ·         "Incorporation of Clinical Observations into Setting Clinically Relevant Specifications for Biologics", Marisa Joubert, PhD (Amgen Inc.)

    ·         "A Mechanism-based Dendritic Cell Migration Assay to Predict Subcutaneous Immunogenicity", Nicole Jarvi, PhD (Merck & Co., Inc)

    ·         "Advanced Characterization of LNPs" (Panelists: Mark Brader, Research Fellow, Moderna; Yulia Eygeris, Assistant Professor, Oregon State University; Suzette Pabit, Associate Principal Scientist, Merck & Co., Inc.; Ryan Schroder, Senior Scientist, Bristol Myers Squibb; Chun-Wan Yen, Senior Principal Scientist, Genentech, Inc.)

    ·         "Connecting physicochemical properties of LNPs to in vivo behavior" (Panelists: Ine Lentacker, Senior Researcher, Univ. of Ghent; Tom Anchordoquy, Professor, Univ. or Colorado, Anshutz; Miffy Cheng, Assistant Professor, Univ. of British Columbia; Jacob Brenner, Assistant Professor, Univ. of Pennsylvania)

    Thank you for your participation in AAPS and the BPABC community!

    The BPABC Leadership Team:

    Mayank Patel (Chair)

    Michaela Cohrs (Secretary)

    Suman Luthra (past-Chair)

    Michael Zaleski (Learning Opportunities)

    Kimya Nourbakhsh (Member Engagement)

    Kevin Gurney (Member Engagement)

    Joshua Tokuda (Learning Opportunities)



    ------------------------------
    Michael Zaleski
    PhD Candidate
    University of Pennsylvania
    Philadelphia PA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------